2025
Imetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstractsBisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma
Yang Z, Chen Q, Dong S, Xu P, Mao Z, Dong Y, Li W, Li W, Han Y, Dai L, Dong G, Zhang Y, Li Y, Cheng L, Ci W, Yu W, Xu C. Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma. Bioengineering & Translational Medicine 2025 DOI: 10.1002/btm2.70004.Peer-Reviewed Original ResearchDetection of urothelial carcinomaStandard urine cytologyDetecting bladder cancerClinical detectionRenal pelvis cancerEarly noninvasive detectionUC tumorsUrine cytologyUrothelial carcinomaMale malignancyPelvis cancerEasy-to-performUreter cancerBladder cancerValidation setPatient enrollmentUrinary systemPatientsUrine samplesNoninvasive detectionUrineCancerEarly detectionCarcinomaMalignancyComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsPhase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
Bewersdorf J, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong W, Abdel-Wahab O, Stein E. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia 2025, 39: 765-769. PMID: 39856223, PMCID: PMC11879867, DOI: 10.1038/s41375-025-02515-8.Peer-Reviewed Original ResearchUsing natural language processing to identify emergency department patients with incidental lung nodules requiring follow‐up
Moore C, Socrates V, Hesami M, Denkewicz R, Cavallo J, Venkatesh A, Taylor R. Using natural language processing to identify emergency department patients with incidental lung nodules requiring follow‐up. Academic Emergency Medicine 2025, 32: 274-283. PMID: 39821298, DOI: 10.1111/acem.15080.Peer-Reviewed Original ResearchNatural language processingIncidental lung nodulesFollow-upChest CTsCT reportsF1 scoreLung nodulesEmergency departmentLanguage processingFollow-up of incidental findingsIncidental findingNatural language processing developersAbsence of malignancyMetrics of precisionNatural language processing pipelineNatural language processing metricsChest CT reportsRecommended follow-upEmergency department patientsFollow-up rateLanguage modelLung cancerReduce errorsMalignancyDepartment patientsChimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes
Puzo C, Siddon A. Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes. Pathology 2025, 57: 267-275. PMID: 39934013, DOI: 10.1016/j.pathol.2024.12.632.Peer-Reviewed Original ResearchLineage specific chimerismChimerism testingMyeloid malignanciesCell burdenHematopoietic cellsPost allogeneic stem cell transplantationHost hematopoietic cellsMalignant cell burdenLeukemic cell burdenStem cell transplantationRisk of relapseRecipient hematopoietic cellsPost-transplant outcomesCell transplantationRelapse detectionRecipient chimerismTherapy decisionsRelapsePercentage of donorsChimerismHigh riskConcurrent useChimerism percentageEarly identificationMalignancy
2024
Performance of Ulcer Features in Predicting Malignancy Among Gastric Ulcers Diagnosed on Upper Endoscopy.
Patel A, Gandle C, Baerman E, Lill I, Pecha R, Nguyen Wenker T, El-Serag H, Ketwaroo G, Tan M. Performance of Ulcer Features in Predicting Malignancy Among Gastric Ulcers Diagnosed on Upper Endoscopy. Journal Of Clinical Gastroenterology 2024 PMID: 39761160, DOI: 10.1097/mcg.0000000000002118.Peer-Reviewed Original ResearchSurveillance endoscopyGastric atrophyIrregular bordersElevated borderGastric ulcerMalignant ulcersUlcer featuresGastric ulcer diagnosisPrevalence of malignancyPredictors of malignancyBenign gastric ulcerBiopsy histopathologyForrest classificationUpper endoscopyPredicting malignancyUlcer diagnosisMalignant featuresEndoscopic appearanceMalignancyPrevalent malignancyEndoscopyBenign ulcerPatientsPredictive valueHistopathologyA Yale Dermatology Perspective on Cutaneous T-Cell Lymphoma: Historical Reflection to Emerging Therapies
Swallow M, Edelson R, Girardi M. A Yale Dermatology Perspective on Cutaneous T-Cell Lymphoma: Historical Reflection to Emerging Therapies. Clinics In Dermatology 2024 PMID: 39694197, DOI: 10.1016/j.clindermatol.2024.12.006.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaMycosis fungoidesSubtype of cutaneous T-cell lymphomaPathogenesis of cutaneous T-cell lymphomaNon-Hodgkin's lymphomaEvolving treatment landscapeSezary syndromeHistological variantsTreatment landscapeLymph nodesSchool of MedicineLymphomaYale School of MedicineFungoidesClinical careMalignancyLymphMycosisSyndromeSubtypesPathogenesisCarbapenem-resistant Enterobacterales in solid organ transplant recipients
Boutzoukas A, Dai W, Cober E, Abbo L, Komarow L, Chen L, Hill C, Satlin M, Grant M, Fries B, Patel G, McCarty T, Arias C, Bonomo R, van Duin D, Investigators F, Kanj S, Jabbour J, Zhang F, Lok J, Salata R, Di Castelnuovo V, Gutierrez J, Cober E, Richter S, Anderson D, Evans B, Hill C, Cross H, Baum K, Arias R, Fowler V, Ordoñez K, Jacob J, Li L, Kreiswirth B, Manca C, Chen L, Desai S, Herc E, Cordova E, Rioseco M, Vichez S, Sanchez M, Valderrama S, Figueroa J, Arias C, Dinh A, Panesso D, Rydell K, Tran T, Hu F, Su J, Jiang J, Wang M, Xu X, Yang Y, Munita J, Spencer M, Alenazi T, Bonomo R, Marshall S, Rudin S, Huskins C, Kerry, Patel R, Schmidt-Malan S, Revolinski S, Wortmann G, Kalayjian R, Weston G, Ostrowsky B, Patel G, Eiras D, Kim A, Garcia-Diaz J, Salcedo S, Farrell J, Liu Z, Henderson A, Paterson D, Xie Q, Kaye K, Gao H, Yu Y, Waters M, Fries B, Eilertson B, Marimuthu K, Chew K, Smitasin N, Tambyah P, Gallagher J, Peleg A, Leroi M, Li L, Komarow L, Ge L, Evans S, McCarty T, Chambers H, Garner O, Abbo L, van Duin D, Lautenbach E, Han J, Doi Y, Wong D, Hanson B, Reyes J, Botero M, Diaz L, Perez F, Banerjee R, Dhar S, Satlin M, Zong Z. Carbapenem-resistant Enterobacterales in solid organ transplant recipients. American Journal Of Transplantation 2024 PMID: 39522694, DOI: 10.1016/j.ajt.2024.10.020.Peer-Reviewed Original ResearchSolid organ transplant recipientsCarbapenem-resistant EnterobacteralesOrgan transplant recipientsTransplant recipientsCohort studyAll-cause 30-day mortalityStabilized inverse probabilityMatched cohort studyCarbapenem resistanceMalignancy historyClinical isolatesAdmitted from homeMatched patientsTransplant historyInfection criteriaAll-causeInverse probabilityMortality riskEnterobacteralesMortalityOutcomesRecipientsMalignancyMulticenterTransplantationFocal and Developing Asymmetries
Tamayo S, Andrejeva L, Singh K. Focal and Developing Asymmetries. 2024, 159-184. DOI: 10.1007/978-3-031-65711-5_6.Peer-Reviewed Original ResearchFocal asymmetryBreast cancerBreast tissueBenign breast tissueFibroglandular tissue densityLikelihood of malignancyComparison mammogramsFibroadenomatoid changeMalignant causesBaseline mammogramMammographic findingsBenign causesSonographic abnormalitiesNon-palpableFat necrosisImaging findingsScreening mammographyArchitectural distortionPosttreatment changesMammographic viewsBreastMalignancyTissue densityCancerMammogramsUtility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.Peer-Reviewed Original ResearchOvarian carcinomaNext generation sequencingPrimary uterine tumorsDiagnostically challenging casesOvarian tumorsPrimary tumorUterine tumorsEndometrial malignancyMetastatic tumorsAdjuvant treatmentClonal relationshipTargeted therapyUtilization of next generation sequencingTumor clonalityGeneration sequencingProtein expression profilesTumorChallenging casesImprove outcomesCarcinomaGold standardGenetic landscapeMalignancyClonalityExpression profilesSquamous Cell Carcinoma of the Pancreas: A Case Report
Nagar A, Rao A, Protiva P. Squamous Cell Carcinoma of the Pancreas: A Case Report. Cureus 2024, 16: e70247. PMID: 39329044, PMCID: PMC11425980, DOI: 10.7759/cureus.70247.Peer-Reviewed Original ResearchUnmet needs in cervical cancer – can biological therapies plug the gap?
Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.Peer-Reviewed Original ResearchBiologic therapyCervical cancerIntroduction of biologic therapiesManagement of cervical cancerImmune checkpoint inhibitorsIncreased overall survivalCurrent treatment recommendationsMultiple tumor typesAntibody-drug conjugatesCheckpoint inhibitorsOverall survivalRecurrent diseaseGynecologic malignanciesTreat malignanciesTumor typesClinical outcomesAngiogenesis inhibitorsBurden of casesTreatment recommendationsTherapyImprove current standardsAntitumor activityInadequate screeningCancerMalignancyTERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao W, Simsir A, Liu X, Brandler T, Cai G. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal Of Clinical Pathology 2024, 163: 251-257. PMID: 39250709, DOI: 10.1093/ajcp/aqae117.Peer-Reviewed Original ResearchTERT promoter mutationsHistopathologic follow-upFine-needle aspirationTERT mutationsMolecular alterationsFollow-upPromoter mutationsThyroid carcinomaFine-needle aspiration diagnosisFine-needle aspiration specimensThyroid fine-needle aspiration specimensBenign thyroid neoplasmsSurgical follow-upAssociated with malignancyMulti-institutional studyThyroSeq v3Thyroid neoplasmsAspiration specimensTumor behaviorMalignant neoplasmsCarcinomaMalignancyNeoplasmsThyroidMutationsEpigenetic control of immunoevasion in cancer stem cells
Galassi C, Esteller M, Vitale I, Galluzzi L. Epigenetic control of immunoevasion in cancer stem cells. Trends In Cancer 2024, 10: 1052-1071. PMID: 39244477, DOI: 10.1016/j.trecan.2024.08.004.Peer-Reviewed Original ResearchCancer stem cellsTumor-targeting immune responsesPopulation of malignant cellsStem cellsResistance to therapyStages of cancer progressionHost immune systemDisease relapseMalignant cellsTumor progressionImmune recognitionNeoplastic cellsImmune responseCancer progressionImmune systemEvade recognitionEpigenetic modification of DNATherapeutic targetCancerEpigenetic modificationsCellsEpigenetic controlModification of DNAImmunotherapyMalignancy54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Langley R, Fiorentino D, Bagel J, Lafferty K, Skobelev E, Langholff W, Lebwohl M, Ho V, Strober B. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab61. DOI: 10.1016/j.jaad.2024.07.252.Peer-Reviewed Original ResearchCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyClonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.Peer-Reviewed Original ResearchClonal hematopoiesis of indeterminate potentialClonal hematopoiesisClonal cytopeniaSomatic genetic alterationsTherapeutic targetStem/progenitor cell populationsRisk stratification toolBlood of individualsMyeloid malignanciesMyeloid neoplasmsHematologic malignanciesPotential therapeutic targetIndeterminate potentialRisk stratificationBlood countGenetic alterationsStratification toolClinical investigationNatural historyCell populationsCytopeniasMalignancyBloodRiskCytopenia(sReevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concernsA newly identified gene Ahed plays essential roles in murine haematopoiesis
Nakai R, Yokota T, Tokunaga M, Takaishi M, Yokomizo T, Sudo T, Shi H, Yasumizu Y, Okuzaki D, Kokubu C, Tanaka S, Takaoka K, Yamanishi A, Yoshida J, Watanabe H, Kondoh G, Horie K, Hosen N, Sano S, Takeda J. A newly identified gene Ahed plays essential roles in murine haematopoiesis. Nature Communications 2024, 15: 5090. PMID: 38918373, PMCID: PMC11199565, DOI: 10.1038/s41467-024-49252-7.Peer-Reviewed Original ResearchConceptsMutant embryonic stem cellsConditional knockoutUncharacterised genesHaematopoietic cellsNuclear proteinsFunctional genesHaematopoiesis in vivoAssociated with malignancyBiological functionsGenesSomatic mutationsEmbryonic stem cellsHaematopoietic developmentTransplantation experimentsHaematological malignanciesDeletionAdult miceCancer patientsCoordinated actionEmbryonic dayStem cellsHaematopoiesisMurine haematopoiesisCellsMalignancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply